The prime objective of the Boston University Alzheimer's Disease Center (BU ADC) is to provide resources to support high impact studies on the pathogenesis, detection, and treatment of Alzheimer's Disease (AD) and related disorders. The leadership team and investigators affiliated with the BU ADC represent a dynamic forward thinking team of clinicians and scientists who have made significant contributions to AD-related research and are committed to advancing the field in the years ahead. The BU ADC consists of an Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Education and Information Transfer Core, and a Translational and Transgenic Core. The BU ADC has four aims.
Aim 1 is to foster and support high-impact, innovative, state of the art research on brain aging and AD by: a) identifying, recruiting, and thoroughly characterizing subjects willing to participate in clinical trials and other cutting-edge clinical research studies;b) collecting, storing, analyzing, and distribute biological samples to support high priority AD-related research;c) conducting state-of the-art diagnostic neuropathological evaluation and maximize CNS tissue donation to support state of the art tissue-based research;and d) fostering innovative AD research through a strong pilot project program.
Aim 2 is to collect and submit high quality data to the Data Management and Statistics Core for timely UDS submissions to the NACC database and for data sharing with qualified AD investigators engaged in cutting edge AD-related research while ensuring data security and integrity.
Aim 3 is to support and inform the communities we serve regarding the benefits of the BU ADC and AD research and to provide a high-quality training environment for professionals at all career levels. The BU ADC has developed innovative approaches to educate medical students about AD and has pioneered methods to increase African American brain donation.
Aim 4 is to breed and disseminate transgenic mouse models of AD and related disorders and to provide specialized technical services to support cutting edge translational AD-related research.

Public Health Relevance

Alzheimer's disease (AD) affects over 5 million people and is the 7th leading cause of death in the USA. Despite advances in understanding of how AD and other age-related diseases cause loss of brain function, much more research is needed on how AD and related disorders develop, how to detect them at their earliest stages, and how to treat them effectively once they develop. The mission of the Boston University Alzheimer's Disease Center is to provide resources to accelerate research addressing these vital questions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG013846-19
Application #
8690700
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
19
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02118
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Li, Dan; Wang, Lei; Maziuk, Brandon F et al. (2018) Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau. J Biol Chem 293:12081-12094
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tagge, Chad A; Fisher, Andrew M; Minaeva, Olga V et al. (2018) Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain 141:422-458
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Chung, Jaeyoon; Wang, Xulong; Maruyama, Toru et al. (2018) Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. Alzheimers Dement 14:623-633
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826

Showing the most recent 10 out of 791 publications